Establishment and application of a determination method for plasma concentrations of venetoclax，busulfan and voriconazole in patients with acute myeloid leukemia
- VernacularTitle:AML患者血浆中维奈克拉、白消安和伏立康唑浓度测定方法的建立与应用
- Author:
Zhenhua ZHANG
1
;
Mengru ZHANG
1
;
Aoxiang GUO
2
;
Hui CHEN
2
;
Shijian XIANG
2
;
Benjie ZHOU
2
;
Bingchen GE
3
Author Information
1. Dept. of Pharmacy，the Seventh Affiliated Hospital （Shenzhen），Sun Yat-sen University，Guangdong Shenzhen 518107，China;School of Pharmaceutical Sciences （Shenzhen），Sun Yat-sen University，Guangdong Shenzhen 518107，China
2. Dept. of Pharmacy，the Seventh Affiliated Hospital （Shenzhen），Sun Yat-sen University，Guangdong Shenzhen 518107，China;Shenzhen Key Laboratory of Chinese Medicine Active Substance Screening and Translational Research，Guangdong Shenzhen 518107，China
3. Dept. of Pharmacy，the Seventh Affiliated Hospital （Shenzhen），Sun Yat-sen University，Guangdong Shenzhen 518107，China
- Publication Type:Journal Article
- Keywords:
venetoclax;
busulfan;
voriconazole;
acute myeloid leukemia;
LC-MS/MS;
therapeutic drug monitoring
- From:
China Pharmacy
2026;37(10):1323-1328
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To establish a method for simultaneous determination of venetoclax， busulfan and voriconazole in plasma of patients with acute myeloid leukemia （AML）， and apply it clinically. METHODS Plasma samples were subjected to protein precipitation using acetonitrile and subsequently analyzed by liquid chromatography-tandem mass spectrometry （LC-MS/MS） using venetoclax-D 8 ， busulfan-D 8 and posaconazole as internal standards. The separation was performed on a Phenomenex Kinetex ® C 18 column with a mobile phase composed of 0.1% formic acid solution （2 mmol/L ammonium acetate）-0.1% formic acid in acetonitrile （gradient elution） at a flow rate of 0.8 mL/min. The column temperature was set at 40 ℃， the sample size was 5 μL， and the total run time was 3.10 min. An electrospray ionization source was employed， and positive ion scanning was conducted using multiple reaction monitoring mode. The ion pairs used for quantitative analysis included m/z 868.4→636.3 （venetoclax）， m/z 264.1→151.1 （busulfan）， and m/z 350.1→224.0 （voriconazole）. The above LC-MS/MS method was adopted to determine plasma concentrations of venetoclax and voriconazole in 10 AML patients， as well as plasma concentration of busulfan in 5 patients undergoing conditioning treatment for allogeneic hematopoietic stem cell transplantation. RESULTS The linear ranges of venetoclax， busulfan and voriconazole were 50-10 000， 15-3 000 and 50-10 000 ng/mL， respectively （ R 2 ≥0.999 0）， with lower limits of quantification of 50， 15 and 50 ng/mL， respectively. The RSDs of intra-day and inter-day precision tests for all three analytes were all less than 10%， with accuracy （relative errors） ranging from －10.00% to 12.96%. The average extraction recovery ranged from 92.54% to 100.95%， and the average matrix effect was 89.98%-101.49%. Dilution reliability covered all dilution factors used in the test samples， and the absolute values of relative errors in stability tests were all≤16.25%. The plasma concentrations of venetoclax， busulfan and voriconazole in enrolled patients were 496.20-4 250.45， 233.48-2 002.28 and 475.51-5 710.18 ng/mL， respectively. CONCLUSIONS The LC-MS/MS method established in this study is rapid， sensitive and easy to operate， and can be used for the therapeutic drug monitoring of venetoclax， busulfan and voriconazole.
